Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 18Unknown 6Terminated 6Recruiting 5Not yet recruiting 3Withdrawn 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 437Neoplasms 322Carcinoma, Non-Small-Cell Lung 250Prostatic Neoplasms 240Lung Neoplasms 174Colorectal Neoplasms 156Pancreatic Neoplasms 148Neoplasm Metastasis 142Leukemia, Myeloid, Acute 140Multiple Myeloma 130Lymphoma 127Carcinoma, Hepatocellular 127Ovarian Neoplasms 109Melanoma 109Brain Neoplasms 101Recurrence 100Head and Neck Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 96Leukemia 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Glioblastoma 85Lymphoma, Non-Hodgkin 83Colonic Neoplasms 79Squamous Cell Carcinoma of Head and Neck 76Lymphoma, Follicular 76Carcinoma, Renal Cell 74Lymphoma, Large B-Cell, Diffuse 71Hematologic Neoplasms 69Sarcoma 60Stomach Neoplasms 58

Interventions

cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Advanced Malignancies × Clear all
NCT05245916 2023-09-05

IBI397 or Combination Therapies in Patients With Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Withdrawn

Advanced Malignancies

NCT02520245 2016-11-07

Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

Regeneron Pharmaceuticals

Phase 1 Withdrawn

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡